Cisplatin plus continuous infusion vinorelbine for the treatment of advanced non-small cell lung cancer: A phase I-II study

Clinical and Translational Oncology

Volumn 8, Issue 7, 2006, Pages 519-524

  Cobo Dols, Manuel ^a   Gil Calle, Silvia ^a   Villar Chamorro, Esther ^a   Alés Díaz, Inmaculada ^a   Carabantes Ocón, Francisco ^a   Alcalde García, Julia ^a   Gutiérrez Calderón, Vanesa ^a   Montesa Pino, Ávaro ^a   Bretón García, Juan J ^a   Benavides Orgaz, Manuel ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Continuous infusion vinorelbine; Maximum tolerated dose; Non small cell lung cancer

Indexed keywords

CISPLATIN; DEXAMETHASONE; SEROTONIN 3 ANTAGONIST; VINORELBINE DITARTRATE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; NAVELBINE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SENSORY DYSFUNCTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 33748864446     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0052-6     Document Type: Article

References (29)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2005. J Clin Oncol. 2004;22(2):550-53.
2. Grilli R, Oxman AD, Julián JM. Chemotherapy is for advanced non-small cell lung cancer. How much benefit is enough? J Clin Oncol. 1995;11:1866-72.
3. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J. 1955;511:899-909.
4. Rahmani R, Martin M, Barbet J, et al. Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5′-Noranhydrovinblastine (Navelbine). Cancer Res. 1984;44:5609-13.
5. Paintrand MR, Pignot I. Navelhine: An ultrastructure study of its effects. J Electron Microscopy. 1983;52:115-24.
6. Cros S, Wright M, Morimoto M, et al. Experimental antitumour activity of navelbine. Semin Oncol. 1989:16(2 Suppl 4):S15-20.
7. Chiappori A, Devore M, Johnson DH, et al. New agents in the management of non-small cell lung cancer: Cancer Control. 1997:4:317-25.
8. Schilling T, Fiebig H, Karpel Fronious S, et al. Clinical phase I and pharmacokinetic trial of navelbine administered as single intravenous bolus every 21 days in cancer patients. Invest New Drugs. 1996; 14:571-8.
9. Mathe G, Reizenstein P. Phase I pharmacologic study of a new vinca-alkaloid: Navelbine. Cancer Lett. 1985;27:285-95.
10. Crawford J, O'Rourke M, Schiller H, et al. Randomized trial with vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV NSCLC. J Clin Oncol. 1996:14:2774-8.
11. Frasci G, Lorusso V, Panza N. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18(15):2529-36.
12. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:66-72.
13. Depierre A, Chastang C, Choix E, et al. Vinorelbine versus vinorelbine plus cis-platin in advanced non-small-cell lung cancer: A randomized trial. Ann Oncol. 1994;5:37-42.
14. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cis-platin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of an European multicenter trial including 612 patients. J Clin Oncol. 1994;12:360-7.
15. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cis-platin in the treatment of patients with advanced non-small-cell lung cancer: A South West Oncology Group trial. J Clin Oncol. 2001;19(13):3210-8.
16. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A South West Oncology Group study. J Clin Oncol. 1998:16:2459-65.
17. Scagliotti GV, Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum based doubles in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285-91.
18. Fosella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatinum for advanced non-small-cell lung cancer: the TAX 526 Study Group. J Clin Oncol. 2005;21(16):3016-24.
19. Comella P, Frasci G, Panza N. Randomized trial comparing cisplatin, gemcitabine and vinorelbine with Either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000;18(7):1451-7.
20. Gridelli C, Gallo C, Shepherd FA. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell-lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2005;21(16):3025-54.
21. Toussaint C, Izzo J, Spielmann M, et al. Phase I/II trial of continous infusion vinorelbine for advance breast cancer. J Clin Oncol. 1994;12:2102-12.
22. Ibrahim NK, Valero V, Rahman Z, et al. Phase I/II trial of vinorelbine (Navelbine) by continuus infusion in patients with metastatic breast cancer: Cumulative toxicities limit dose escalation. Cancer Invest. 2001;19:459-66.
23. Carabante-Ocón F, Cobo-Dols M, Benavides Orgaz M. Continuous-infusion vine-relbine for the treatment of advanced non-small-cell lung cancer: A phase I/II study. Clin Lung Cancer. 2005:7:121-6.
24. Berthaud P, Le Chevalier T, Ruffie P, et al. Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small-cell lung cancer. Eur J Cancer. 1992; 28A:1865-5.
25. Jackson DV. The periwinkle alkoloids, in: Lockich JJ, ed: Cancer Chemotherapy by infusion, vol 10. Chicago: Precept; 1990. p. 155-75.
26. Yap HY, Blumenschein GR, Keatin MJ, et al. Viliblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep. 1980;64:279-85.
27. Yau JC, Yap HY, Buzdar AU, et al. A comparative randomized trial of vinca alkaloids in patients with metastatic carcinoma. Cancer. 1985;55:537-40.
28. Fraschini G, Yap YY, Hortobagy GN, et al. Five-day continuous-infusion viablastine in the treatment of breast cancer. Cancer. 1985;56:225-9.
29. Rahmani R, Bruno R, Iliadis A, et al. Clinical pharmacokinetic of the antitumor drug navelbine(5′-noranhydrovinblastine). Cancer Res. 1987;47:5796-99.